Cala Health closed a $50 million funding round. The Silicon Valley-based company sells an FDA-cleared wearable device that temporarily relieves hand tremors in people with essential tremor and Parkinson’s disease. The post Cala Health Snags $50M for At-Home Tremor Relief Therapy appeared first on MedCity News.
That is the title of my recent paper with co-authors Denise Clayton, Glorian Yen, Lincy Geevarghese, Yulin Shi Anem Waheed. The abstract is below. IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease associated with complications that increase morbidity, such as thrombosis and chronic kidney disease. Limited data exist regarding complications among treated patients outside…
CMS official acknowledges that piecemeal approach to extensions is challenging for program operations and long-term planning
This edition examines the role of news influencers in spreading misinformation, misleading narratives about harm reduction amid disparities in opioid overdose, and biases in artificial intelligence (AI) in healthcare.
Today’s patients are used to the seamless and transparent payment processes in retail services. It’s no surprise that they expect the same convenience with paying for healthcare. According to Experian Health’s State of Patient Access 2024 report, 96% emphasized that it is crucial they receive an accurate estimate of treatment costs before service. In fact,…
As bird flu continues to spread among animals in the U.S., KFF’s Tracking Poll on Health Information and Trust finds that the public is more concerned about its impact on food prices than potential health impacts. Trust in the CDC to provide information on bird flu is also divided along partisan lines, and a large…
Mientras la epidemia de sarampión más grave en una década ha causado la muerte de dos niños y se ha extendido a 27 estados sin dar señales de desacelerar, las creencias sobre la seguridad de la vacuna contra esta infección y la amenaza de la enfermedad se polarizan rápido, alimentadas por las opiniones antivacunas del…
That is the argument from an interesting post on the Carcinisation website titled “A Case Against the Placebo Effect“. In short, the authors argue that placebos in-and-of-themselves may have small impact out health outcomes. However, care practices in clinical trials may be different such that health outcomes improve or people feel more cared for in…
David Dyke is the Chief Product Officer of Relatient, which is one of the biggest players in the up and coming area of direct patient scheduling. As anyone who has been stuck in a phone tree or tried to reach a live human just to get an appointment at a doctor’s office knows, scheduling in…
Calling the costs ‘unprecedented’ in CMS Innovation Center models, the VBID model cost CMS $2.3 billion in CY 2021 and $2.2 billion in CY 2022